Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

20171,375 citationsJournal Articlebronze Open Access

Authors

Gϋnter von Minckwitz · German Breast group

Marion Procter

Evandro de Azambuja

Dimitrios Zardavas · Breast International Group

Mark Benyunes · Roche (Switzerland)

Giuseppe Viale · University of Milan

Thomas Suter · University Hospital of Bern

Amal Arahmani

Abstract

Pertuzumab significantly improved the rates of invasive-disease-free survival among patients with HER2-positive, operable breast cancer when it was added to trastuzumab and chemotherapy. Diarrhea was more common with pertuzumab than with placebo. (Funded by F. Hoffmann-La Roche/Genentech; APHINITY ClinicalTrials.gov number, NCT01358877 .).

Topics & Keywords

HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 377, Issue 2, pp. 122-131

DOI: 10.1056/nejmoa1703643

Field-Weighted Citation Impact: 65.93